Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 71 results for parkinson

  1. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941

    Awaiting development [GID-TA11481] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  3. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

    Evidence summary
    Published
    6 October 2015

  4. There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and personal social services. Some impacts may not have been included in the external assessment group's (EAG) model because of a lack of data (see section 3.12 ), including resource use related to carers (see section 3.13 ). Adopting the technologies may change how care is provided (see section 3.4 ) so their effect on resources is hard to estimate without direct data. So, the committee recommended collecting data on how much using the devices affects resource use, to inform cost-effectiveness estimates. Data on time dedicated to training and spent reviewing device results should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.

    should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered. Any...

    Research recommendation
    Published
    7 March 2023

  5. Multiple long-term conditions: multimorbidity register (IND205)

    This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184

    General practice indicators suitable for use in QOF
    Published
    31 July 2019

  6. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

    Evidence summary
    Published
    30 September 2014

  7. Psychotic symptoms (hallucinations and delusions):- What is the effectiveness of rivastigmine compared with atypical antipsychotic drugs for treating psychotic symptoms (particularly hallucinations and delusions) associated with Parkinson's disease?

    used to treat Parkinson's disease psychosis because it has shown some effectiveness in improving behavioural symptoms in people with...

    Research recommendation
    Published
    15 October 2018

  8. Hypersexuality: fluoxetine (ESUOM46)

    Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

    Evidence summary
    Published
    21 July 2015

  9. Depression in adults (QS8)

    This quality standard covers the clinical assessment and management of depression in adults aged 18 and over. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    29 June 2023
    View quality statements

    Sections for QS8

  10. Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome (IPG362)

    Evidence-based recommendations on percutaneous posterior tibial nerve stimulation for overactive bladder syndrome. This involves inserting a fine needle into a nerve just above the ankle and passing a mild electric current to the nerves that control bladder function.

    Interventional procedures guidance
    Published
    27 October 2010
    View recommendations

    Sections for IPG362

  11. QTUG for assessing falls risk and frailty (MIB73)

    NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)

    Medtech innovation briefing
    Published
    26 July 2016

  12. YOURmeds for medication support in long-term conditions (MIB289)

    NICE has developed a medtech innovation briefing (MIB) on YOURmeds for medication support in long-term conditions .

    Medtech innovation briefing
    Last updated
    9 June 2023

  13. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (IPG617)

    Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).

    Interventional procedures guidance
    Published
    20 June 2018
    View recommendations

    Sections for IPG617

  14. What is the effectiveness of statin therapy in older people?

    preventing or promoting other chronic diseases of ageing such as dementia, Parkinson's disease, or age-related macular degeneration....

    Research recommendation
    Published
    9 June 2015

  15. How frequently the remote monitoring devices were modelled as being used substantially affected the cost-effectiveness estimates in the EAG's model (see section 3.9 ). There are many ways the devices could be used in the NHS (see section 3.3 ) and no data was available to compare different approaches. So, it is currently not possible to highlight particular approaches that are likely to be more clinically and cost effective. Centres using the devices should therefore collect data on how often they are used and under what circumstances. For example, regularly in advance of scheduled review appointments, to indicate when such appointments are needed, or targeted to people having issues with symptoms. This will help assess the clinical and cost effectiveness of the different uses of the devices in NHS practice.

    details Comes from guidance Devices for remote monitoring of Parkinson's disease Number DG51 Date issued January 2023

    Research recommendation
    Published
    7 March 2023